

Attorney Docket No. 9233-71

1646
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Soltero et al.

Confirmation No.: 3700

Serial No.: 10/036,744

Group Art Unit: 1646

Filed: December 21, 2001

For: *METHODS OF SYNTHESIZING INSULIN POLYPEPTIDE-OLIGOMER
CONJUGATES, AND PROINSULIN POLYPEPTIDE-OLIGOMER CONJUGATES
AND METHODS OF SYNTHESIZING SAME*

Date: January 31, 2003


Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Attached is a form PTO-1449, together with a copy of the identified document(s). This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(b), within three months of the filing date of the above-referenced application or before the mailing of a first Office Action on the merits, whichever event occurs last. Accordingly, no fee is required. The Commissioner is authorized to charge any additional fee, or credit any refund, to our Deposit Account No. 50-0220.

Respectfully submitted,


Michael Strickland
Registration No. 47,115




20792

PATENT TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Washington, DC 20231, on January 31, 2003.


Monica L. Croom


RECEIVED
FEB 04 2003
TECH CENTER 1600/2900

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office				Attorney Docket Number 9233-71		Serial No. 10/036,744	
LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)				Applicants: Soltero et al.			
				Filing Date: December 21, 2001		Group	
U. S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	1.	3,919,411	11/11/75	Glass et al.			
	2.	3,256,153	06/14/66	Heimlech			
	3.	4,003,792	01/18/77	Mill et al.			
	4.	4,044,196	08/23/77	Huper et al.			
	5.	4,087,390	05/02/78	Shields			
	6.	4,093,574	06/06/78	Shields			
	7.	4,100,117	07/11/78	Shields			
	8.	4,229,438	10/21/80	Fujino et al.			
	9.	4,253,998	03/03/81	Sarantakis			
	10.	4,277,394	07/07/81	Fujino et al.			
	11.	4,338,306	07/06/82	Kitao et al.			
	12.	4,348,387	09/07/82	Brownlee et al.			
	13.	4,410,547	10/18/83	Ueno et al.			
	14.	4,469,681	09/04/84	Brownlee et al.			
	15.	4,472,382	09/18/84	Labrie et al.			
	16.	4,579,730	04/01/86	Kidron et al.			
	17.	4,585,754	04/29/86	Meisner et al.			
	18.	4,622,392	11/11/86	Hong et al.			
	19.	4,684,524	08/04/87	Eckenhoff et al.			
	20.	4,698,264	10/06/87	Steinke			
	21.	4,717,566	01/05/88	Eckenhoff et al.			
	22.	4,744,976	05/17/88	Snipes et al.			
	23.	4,772,471	09/20/88	Vanlerberghe et al.			
	24.	4,797,288	01/10/89	Sharma et al.			
	25.	4,839,341	06/13/89	Massey et al.			

EXAMINER
 *EXAMINER

DATE CONSIDERED


Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office				Attorney Docket Number 9233-71		Serial No. 10/036,744	
LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)							
				Applicants: Soltero et al.			
				Filing Date: December 21, 2001		Group	
26.	4,840,799	06/20/89	Applegren et al.				
27.	4,849,405	07/18/89	Ecanow				
28.	4,917,888	04/17/90	Katre et al.				
29.	4,935,246	06/19/90	Ahrens				
30.	4,946,828	08/07/90	Markussen				
31.	4,957,910	09/18/90	Sutton et al.				
32.	4,963,367	10/16/90	Ecanow				
33.	4,994,439	02/19/91	Longenecker et al.				
34.	5,013,556	05/07/91	Woodle et al.				
35.	5,055,300	10/08/91	Gupta				
36.	5,055,304	10/08/91	Makino et al.				
37.	5,089,261	02/18/92	Nitecki et al.				
38.	5,093,198	03/03/92	Speaker et al.				
39.	5,162,430	11/10/92	Rhee et al.				
40.	5,164,366	11/17/92	Balschmidt et al.				
41.	5,206,219	04/27/93	Desai				
42.	5,283,236	02/01/94	Chiou				
43.	5,286,637	02/15/94	Veronese et al.				
44.	5,292,802	03/08/94	Rhee et al.				
45.	5,308,889	05/03/94	Rhee et al.				
46.	5,312,808	05/17/94	Shorr et al.				
47.	5,324,775	06/28/94	Rhee et al.				
48.	5,328,955	07/12/94	Rhee et al.				
49.	5,405,621	04/11/95	Sipos				
50.	5,413,791	05/09/95	Rhee et al.				
51.	5,415,872	05/16/95	Sipos				
52.	5,444,041	08/22/95	Owen et al.				
53.	5,446,091	08/29/95	Rhee et al.				
54.	5,461,031	10/24/95	De Felippis				

EXAMINER
 *EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office				Attorney Docket Number 9233-71		Serial No. 10/036,744	
LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)							
				Applicants: Soltero et al.			
				Filing Date: December 21, 2001		Group	
	55.	5,468,478	11/21/95	Saifer et al.			
	56.	5,504,188	04/02/96	Baker et al.			
	57.	5,506,203	04/09/96	Backstrom et al.			
	58.	5,518,998	05/21/96	Backstrom et al.			
	59.	5,523,348	06/04/96	Rhee et al.			
	60.	5,529,915	06/25/96	Phillips et al.			
	61.	5,550,188	08/27/96	Rhee et al.			
	62.	5,545,618	08/13/96	Buckley et al.			
	63.	5,606,038	02/25/97	Regen			
	64.	5,612,460	03/18/97	Zalipsky			
	65.	5,631,347	05/20/97	Baker et al.			
	66.	5,637,749	06/10/97	Greenwald			
	67.	5,650,388	07/22/97	Shorr et al.			
	68.	5,658,878	08/19/97	Backstrom et al.			
	69.	5,681,567	10/28/97	Martinez et al.			
	70.	5,693,609	12/02/97	Baker et al.			
	71.	5,693,769	12/02/97	Kahne et al.			
	72.	5,707,648	01/13/98	Yiv			
	73.	5,738,846	04/14/98	Greenwald et al.			
	74.	5,747,445	05/05/98	Backstrom et al.			
	75.	5,747,642	05/05/98	De Felippis			
	76.	5,766,620	06/16/98	Heiber et al.			
	77.	5,824,638	10/20/98	Burnside et al.			
	78.	5,830,853	11/03/98	Backstrom et al.			
	79.	5,830,918	11/03/98	Sportsman et al.			
	80.	5,849,860	12/15/98	Hakimi et al.			
	81.	5,853,748	12/29/98	New			
	82.	5,854,208	12/29/98	Jones et al.			
	83.	5,856,451	01/05/99	Olsen et al.			

EXAMINER
 *EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office					Attorney Docket Number 9233-71		Serial No. 10/036,744	
LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)					Applicants: Soltero et al.			
					Filing Date: December 21, 2001		Group	
	84.	5,866,538	02/02/99	Norup et al.				
	85.	5,874,111	02/23/99	Maitra et al.				
	86.	5,898,028	04/27/99	Jensen et al.				
	87.	5,902,588	05/11/99	Greenwald et al.				
	88.	5,907,030	05/25/99	Shen et al.				
	89.	5,932,462	08/03/99	Harris et al.				
	90.	5,942,248	08/24/99	Barnwell				
	91.	5,948,751	09/07/99	Kimer et al.				
	92.	5,952,008	09/14/99	Backstrom et al.				
	93.	5,952,297	09/14/99	De Felippis et al.				
	94.	5,968,549	10/19/99	New et al.				
	95.	5,969,040	10/19/99	Hallahan et al.				
	96.	5,981,709	11/09/99	Greenwald et al.				
	97.	5,985,263	11/16/99	Lee et al.				
	98.	6,004,574	12/21/99	Backstrom et al.				
	99.	6,025,325	02/15/00	Campfield et al.				
	100.	6,034,054	03/07/00	De Felippis et al.				
	101.	6,043,214	03/28/00	Jensen et al.				
	102.	6,051,551	04/18/00	Hughes et al.				
	103.	6,063,761	05/16/00	Jones et al.				
	104.	6,093,391	07/25/00	Kabanov et al.				
	105.	6,113,906	09/05/00	Greenwald et al.				
	106.	6,165,976	12/26/00	Backstrom et al.				
	107.	6,177,087	01/23/01	Greenwald et al.				
	108.	6,200,602	03/13/01	Watts et al.				
	109.	6,211,144	04/03/01	Havelund				
	110.	6,248,363	06/19/01	Patel et al.				
	111.	6,251,856	06/26/01	Markussen et al.				
	112.	6,258,377	07/10/01	New et al.				

EXAMINER

*EXAMINER

DATE CONSIDERED


Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office				Attorney Docket Number 9233-71		Serial No. 10/036,744	
LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)							
				Applicants: Soltero et al.			
				Filing Date: December 21, 2001		Group	
	113.	6,268,335	07/31/01	Brader			
	114.	6,306,440	10/23/01	Backstrom et al.			
	115.	6,310,038	10/30/01	Havelund			
	116.	6,323,311	11/27/01	Liu et al.			
	117.	6,335,316	01/01/02	Hughes et al.			
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation Yes No
	118.	EP 0 031 567	07/08/81	EPO			
	119.	WO 93/01802	02/04/93	PCT			Yes - abstract
	120.	WO 95/09831	04/13/95	PCT			
	121.	EP 0 483 465	08/02/95	EPO			Yes - claims
	122.	WO 95/30641	11/16/95	PCT			
	123.	EP 0 597 007	10/16/96	EPO			
	124.	EP 0 621 777	11/09/96	EPO			Yes - claims
	125.	WO 98/07745	02/26/98	PCT			
	126.	EP 0 797 615	01/13/99	EPO			
	127.	WO 99/32134	07/01/99	PCT			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	128.	Abuchowski, A. and F. F. Davis, "Soluble Polymer-Enzyme Adducts," pp. 368-383, Enzymes as Drugs, J. S. Holcenberg, John Wiley, 1981.					
	129.	Akiyama, M. et al., "The Synthesis of New Derivatives of 1-.beta.-D-Arabinofuranosylcytosine," Chem. Pharm. Bull., 1978, 26(3): p. 981-984					
	130.	Allcock et al., "Contemporary Polymer Chemistry," 394-403 (2nd. ed., 1991).					
	131.	Ansell, S. et al., "Application of Oligo-(14-amino-3,6,9,12-tetraoxatetradecanoic acid) Lipid Conjugates as Steric Barrier Molecules in Liposomal Formulations," Bioconjugate Chem., 10: 653-666 (1999).					
	132.	Aoshima, M. et al., "N.sup.4 -Behenoyl-1-.beta.-D-Arabinofuranosylcytosine as a Potential New Antitumor Agent," Cancer Research, 1977, 37: pp. 2481-2486.					
	133.	Baker, D. C. et al., "Prodrugs of 9-.beta.-D-Arabinofuranosyladenine. 1. Synthesis and Evaluation of Some 5'-(O-Acyl) Derivatives," J. Med. Chem., 1978, 21(12): pp. 1218-1221.					
	134.	Banting, R. G., et al., "Pancreatic Extracts in the Treatment of Diabetes Mellitus," The Canadian Med. Assoc. J. 1992, 12: 141-146.					
	135.	Baudys et al., "Stabilization and Intestinal Absorption of Human Calcitonin," J. Contr. Rel. vol. 39, pp. 145-51 (1996).					

EXAMINER
 *EXAMINER

DATE CONSIDERED


Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary) 		Attorney Docket Number 9233-71 Applicants: Soltero et al. Filing Date: December 21, 2001		Serial No. 10/036,744 RECEIVED FEB 04 2003 TECH CENTER 1600/2900
				Group
136.	Baudys, M. et al, "Synthesis and Characterization of Different Glycosylated Derivatives of Insulin" Proceed. Intern. Symp. Cont. Rel. Bioactive. Mater., 1992, 19: 210-211.			
137.	Boccu, E. et al., "Pharmacokinetic Properties of Polyethylene Glycol Derivatized Superoxide Dismutase," Pharm. Res. Comm., 1982 14: 113-120.			
138.	Brange, J. et al, "Chemical Stability of Insulin. 1. Hydrolytic Degradation During Storage of Pharmaceutical Preparations," Pharm. Res., 1992, 9 (6): 715-726.			
139.	Brange, J. et al, "Chemical Stability of Insulin. 2. Formation of Higher Molecular Weight Transformation Products During Storage of Pharmaceutical Preparations," Pharm. Res., 1992, 9 (6) 727-734.			
140.	Chen et al., "Synthesis and Properties of AMA Amphiphiles," J. Org. Chem., 64: 6870-6873 (1999).			
141.	Chien, Y. W., Novel Drug Delivery Systems, pp. 678-679, Marcell Deffer, Inc., New York, N.Y., 1992.			
142.	Conradi, R.A., et al., "The Influence of Peptide Structure on Transport Across Caco-2 Cells," Pharm. Res., 1991, 8(12): 1453-1459.			
143.	Coombes, A.G.A. et al., "Biodegradable Polymeric Microparticles for Drug Delivery and Vaccine Formulation: the Surface Attachment of Hydrophilic Species Using the Concept of Poly(Ethylene Glycol) Anchoring Segments," Biomaterials, 18: 1153-1161 (1997).			
144.	Coudert et al., "A Novel, Unequivocal Synthesis of Polyethylene Glycols," Synthetic Communications, 16(1): 19-26 (1986).			
145.	Delgado et al.; "The Uses and Properties of PEG-Linked Proteins" Critical Reviews in Therapeutic Drug Carrier Systems 9:3,4 249-304 (1992).			
146.	Engel et al.; "Insulin: Intestinal Absorption as Water-in-Oil-in-Water Emulsions" NATURE 219 856-857 (1968).			
147.	Fasano, Alessio; "Innovative strategies for the oral delivery of drugs and peptides" TIBTECH 16 152-157 (1998).			
148.	Francis et al., "Polyethylene Glycol Modification: Relevance of Improved Methodology to Tumour Targeting," J. Drug Targeting, 3: 321-340 (1996).			
149.	Gish, D. T. et al., "Nucleic Acids. 11. Synthesis of 5'-Esters of 1-.beta.-D-Arabinofuranosylcytosine Possessing Antileukemic and Immunosuppressive Activity," J. Med. Chem., 1971, 14(12): pp. 1159-1162.			
150.	Gombotz et al., "Biodegradable Polymers for Protein and Peptide Drug Delivery," Bioconjugate Chem., 6: 332-351 (1995).			
151.	A. Guzman & R. Garcia, "Effects of Fatty Ethers and Stearic Acid on the Gastrointestinal Absorption of Insulin," PRHSJ, 9(2): 155-159 (1990).			
152.	Harris, J. Milton, "Laboratory Synthesis of Polyethylene Glycol Derivatives," J. Macromol. Science - Rev. Macromol. Chem. Phys., C25(3): 325-373 (1985).			
153.	Hostetler, K. Y. et al., "Synthesis and Antiretroviral Activity of Phospholipid Analogs of Azidothymidine and Other Antiviral Nucleosides," The Journal of Biological Chemistry, 1990, 265(11): pp. 6112-6117.			
154.	Hong, C. I. et al., "Nucleoside Conjugates. 7. Synthesis and Antitumor Activity of 1-.beta.-D-Arabinofuranosylcytosine Conjugates of Ether Lipids," J. Med. Chem., 1986, 29: pp. 2038-2044.			
155.	Igarashi, R. et al, "Biologically Active Peptides Conjugated with Lecithin for DDS" Proceed. Intern. Symp. Cont. Rel. Bioactiv. Mater. 1990, 17 367-368.			
156.	King et al.; "Preparation of Protein Conjugates with Alkoxypolyethylene Glycols" Int. J. Peptide Protein Res. 16 147-155 (1980).			
157.	D.G. Lindsay & S. Shall, "The Acetylation of Insulin," Biochem. J., 121: 737-745 (1971).			
158.	M. Maislos et al, "The Source of the Circulating Aggregate of Insulin in Type I Diabetic Patients is Therapeutic Insulin" J. Clin. Invest., 1986, 77: 717-723.			

 EXAMINER
 *EXAMINER

DATE CONSIDERED


Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)		Attorney Docket Number 9233-71		Serial No. 9/036,744
		Applicants: Soltero et al.		
		Filing Date: December 21, 2001	Group	
159.	Mesiha et al., "Hypoglycaemic effect of oral insulin preparations containing Brij 35, 52, 58 or 92 and stearic acid," J. Pharm. Pharmacol., 33: 733-734 (1981).			
160.	Neubauer et al., "Influence of Polyethylene Glycol Insulin on Lipid Tissues of Experimental Animals," Diabetes, 32: 953-958 (Oct. 1983).			
161.	Nucci, et al. "The Therapeutic Value of Poly(ethylen Glycol)--Modified Proteins" Ac. Drug. Del. Rev. 6: 133-151 1991.			
162.	Oka, K. et al, "Enhanced Intestinal Absorption of a Hydrophobic Polymer-conjugated Protein Drug, Smancs, in an Oily Formulation" Pharm. Res., 1990, 7 (8): 852-855.			
163.	Patel et al. "Oral Administration of Insulin By Encapsulation Within Liposomes" FEBS Lett. 62(1) 60-63 1976.			
164.	Price, JC, <i>Polyethylene Glycol</i> , 355-361.			
165.	Ratner, R. E. et al, "Persistent Cutaneous Insulin Allergy Resulting from High-Molecular Weight Insulin Aggregates," Diabetes, 1990, 39: 728-733.			
166.	Robbins, D. C. et al, "Antibodies to Covalent Aggregates of Insulin in Blood of Insulin-Using Diabetic Patients" Diabetes, 1987, 36: 838-841.			
167.	Russell-Jones, G. J. "Vitamin B12 Drug Delivery", Proceed. Intern. Symp. Control. Rel. Bioactive. Mater., 1992, 19: 102-103.			
168.	Saffran et al. "A Model for the Study of the Oral Administration of Peptide Hormones" Can J Biochem 57 548-553 1979.			
169.	Saffran, M. et al, "A New Approach to the Oral Administration of Insulin and Other Peptide Drugs," Science, 1986, 233: 1081-1084.			
170.	Santiago, N. et al, "Oral Immunization of Rats with Influenza Virus M Protein (M1) Microspheres," Proceed. Intern. Symp. Cont. Rel. Bioactive. Mater., 1992, 19: 116-117.			
171.	Savva et al., "Effect of PEG Homopolymer and Grafted Amphiphilic PEG-Palmityl on the Thermotropic Phase Behavior of 1,2-Dipalmitoyl-SN-Glycero-3-Phosphocholine Bilayer," Journal of Liposome Research, 9(3): 357-365 (1999).			
172.	Shen et al., "(C) Means to Enhance Penetration, (3) Enhancement of polypeptide and protein absorption by macromolecular carriers via endocytosis and transcytosis," Advanced Drug Delivery Reviews, 8: 93-113 (1992).			
173.	Shichiri et al.; "Enteral Absorption of Water-in-Oil-in-Water Insulin Emulsions in Rabbits" Diabetologia 10 317-321 (1974).			
174.	G. Sirokman & G.D. Fasman, "Refolding and proton pumping activity of a polyethylene glycol-bacteriorhodopsin water-soluble conjugate," Protein Science, 2: 1161-1170 (1993).			
175.	Szeleifer, I. et al., "Spontaneous Liposome Formation Induced by Grafted Poly(Ethylene Oxide) Layers: Theoretical Prediction and Experimental Verification," Proceedings of the National Academy of Sciences of the United States of America, 95(3): 1032-1037 (Feb. 3, 1998).			
176.	Taniguchi, T. et al, "Synthesis of Acyloyl Lysozyme and Improvement of its Lymphatic Transport Following Small Intestinal Administration in Rats" Proceed. Intern. Symp. Control. Rel. Bioactiv. Mater., 1992, 19: 104-105.			
177.	V.P. Torchilin, "Immunoliposomes and PEGylated Immunoliposomes: Possible Use for Targeted Delivery of Imaging Agents," Immunomethods, 4: 244-258 (1994).			
178.	Tyle, Praveen, " Iontophoretic Devices for Drug Delivery," Pharma Research, 3:6 318-326 (1986).			
179.	J. Wei & G.D. Fasman, "A Poly(ethylene glycol) Water-soluble Conjugate of Porin: Refolding to the Native State," Biochemistry, 34:6408-6415 (1995).			
180.	Zalipsky, S. et al., "Attachment of Drugs to Polyethylene Glycols," Eur. Polym. J., 1983, 19(12): pp. 1177-1183.			

EXAMINER
 *EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)		Attorney Docket Number 9233-71	Serial No. 10/036,744
		Applicants: Soltero et al.	
		Filing Date: December 21, 2001	Group
	181.	Zalipsky et al., "Peptide Attachment to Extremities of Liposomal Surface Grafted PEG Chains: Preparation of the Long-Circulating Form of Laminin Pentapeptide, YIGSR," Bioconjugate Chem. 6: 705-708 (1995).	

RECEIVED
 FEB 04 2003
 TECH CENTER 1001/2900

EXAMINER _____
 *EXAMINER _____

DATE CONSIDERED _____

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.